478 related articles for article (PubMed ID: 16392887)
1. Strategies of tumor immune evasion.
Seliger B
BioDrugs; 2005; 19(6):347-54. PubMed ID: 16392887
[TBL] [Abstract][Full Text] [Related]
2. Tumor escape from immune surveillance.
Costello RT; Gastaut JA; Olive D
Arch Immunol Ther Exp (Warsz); 1999; 47(2):83-8. PubMed ID: 10202560
[TBL] [Abstract][Full Text] [Related]
3. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
4. Tumor-host immune interactions and dendritic cell dysfunction.
Yang L; Carbone DP
Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
6. [Mechanisms of tumor escape from immunologic response].
Costello RT; Gastaut JA; Olive D
Rev Med Interne; 1999 Jul; 20(7):579-88. PubMed ID: 10434348
[TBL] [Abstract][Full Text] [Related]
7. [Molecular bases of cancer immunology].
Barrera-Rodríguez R; Peralta-Zaragoza O; Madrid-Marina V
Salud Publica Mex; 1995; 37(4):344-53. PubMed ID: 7502157
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of immune evasion in breast cancer.
Bates JP; Derakhshandeh R; Jones L; Webb TJ
BMC Cancer; 2018 May; 18(1):556. PubMed ID: 29751789
[TBL] [Abstract][Full Text] [Related]
9. Improving cancer immunotherapy by targeting tumor-induced immune suppression.
Stewart TJ; Smyth MJ
Cancer Metastasis Rev; 2011 Mar; 30(1):125-40. PubMed ID: 21249424
[TBL] [Abstract][Full Text] [Related]
10. [Immune system and tumors].
Terme M; Tanchot C
Ann Pathol; 2017 Feb; 37(1):11-17. PubMed ID: 28159405
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.
Seliger B
HLA; 2016 Nov; 88(5):213-220. PubMed ID: 27659281
[TBL] [Abstract][Full Text] [Related]
12. [Immune response and cancer].
El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
[TBL] [Abstract][Full Text] [Related]
13. Principles of tumor immunosurveillance and implications for immunotherapy.
Ochsenbein AF
Cancer Gene Ther; 2002 Dec; 9(12):1043-55. PubMed ID: 12522443
[TBL] [Abstract][Full Text] [Related]
14. Challenges and prospects of immunotherapy as cancer treatment.
Rescigno M; Avogadri F; Curigliano G
Biochim Biophys Acta; 2007 Sep; 1776(1):108-23. PubMed ID: 17720322
[TBL] [Abstract][Full Text] [Related]
15. [The interplay of immunotherapy and chemotherapy, a novel approach].
Hanoteau A; Henin C; Moser M
Med Sci (Paris); 2016 Apr; 32(4):353-61. PubMed ID: 27137692
[TBL] [Abstract][Full Text] [Related]
16. T-cell death and cancer immune tolerance.
Lu B; Finn OJ
Cell Death Differ; 2008 Jan; 15(1):70-9. PubMed ID: 18007660
[TBL] [Abstract][Full Text] [Related]
17. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
Mocellin S; Nitti D
Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
[TBL] [Abstract][Full Text] [Related]
18. MHC class I down-regulation: tumour escape from immune surveillance? (review).
Bubeník J
Int J Oncol; 2004 Aug; 25(2):487-91. PubMed ID: 15254748
[TBL] [Abstract][Full Text] [Related]
19. MHC class I antigens and immune surveillance in transformed cells.
Aptsiauri N; Cabrera T; Garcia-Lora A; Lopez-Nevot MA; Ruiz-Cabello F; Garrido F
Int Rev Cytol; 2007; 256():139-89. PubMed ID: 17241907
[TBL] [Abstract][Full Text] [Related]
20. Sweet escape: sialic acids in tumor immune evasion.
Büll C; den Brok MH; Adema GJ
Biochim Biophys Acta; 2014 Aug; 1846(1):238-46. PubMed ID: 25026312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]